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A B S T R A C T
Cancer cells often exhibit altered epigenetic signatures that can misregulate genes involved in pro-
cesses such as transcription, proliferation, apoptosis and DNA repair. As regulation of chromatin structure
is crucial for DNA repair processes, and both DNA repair and epigenetic controls are deregulated in many
cancers, we speculated that simultaneously targeting both might provide new opportunities for cancer
therapy. Here, we describe a focused screen that proﬁled small-molecule inhibitors targeting epigenetic
regulators in combination with DNA double-strand break (DSB) inducing agents. We identify UNC0638,
a catalytic inhibitor of histone lysine N-methyl-transferase G9a, as hypersensitising tumour cells to low
doses of DSB-inducing agents without affecting the growth of the non-tumorigenic cells tested. Similar
effects are also observed with another, structurally distinct, G9a inhibitor A-366. We also show that small-
molecule inhibition of G9a or siRNA-mediated G9a depletion induces tumour cell death under low DNA
damage conditions by impairing DSB repair in a p53 independent manner. Furthermore, we establish
that G9a promotes DNA non-homologous end-joining in response to DSB-inducing genotoxic stress. This
study thus highlights the potential for using G9a inhibitors as anti-cancer therapeutic agents in combi-
nation with DSB-inducing chemotherapeutic drugs such as etoposide.
© 2016 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY
license (http://creativecommons.org/licenses/by/4.0/).
Introduction
Cancer cells frequently exhibit sustained proliferation, evasion
of checkpoints, resistance to cell death signals, and activation of path-
ways that promote cancer invasion and metastasis [1]. These
pathways are under intense investigation to better understand cancer
biology and develop targeted therapies. Recently, it has become clear
that cancer cells also often display altered epigenetic signatures at
the chromatin and transcriptional levels, thus promoting research
and drug discovery into epigenetic-focused cancer therapies [2].
Genes encoding enzymes that create histone methylation marks
such as nuclear receptor binding SET-domain proteins 1, 2 and 3
(NSD1, NSD2 and NSD3), SET domain containing 2 (SETD2) and
others undergo recurrent translocations and/or coding mutations
in various cancer types (reviewed in Reference 2). Another enzyme,
DOT1L, which generates the histone H3K79me2mark, has emerged
as a promising epigenetic drug target, as its small molecule-
mediated inhibition selectively kills mixed lineage leukaemia (MLL)
cells [3]. Heterodimeric methyl-transferases G9a/EHMT2 and GLP/
EHMT1 mediate monomethylation and dimethylation of lysine 9 of
histone H3 [4]. Elevated expression of G9a is associated with poor
prognosis in aggressive lung cancer, and dysregulates epigenetic
pathways in lung tumorigenesis [5]. Such studies thus highlight the
potential for G9a/GLP inhibitors in cancer drug development. Cur-
rently, perhaps themost prominent compounds targeting epigenetic
mechanisms are those targeting bromodomain and extra-terminal
motif (BET) proteins that exhibit strong eﬃcacy in selectively killing
cells comprising a wide range of haematologic malignancies [6–9].
Such ﬁndings have underscored the potential of epigenetic inhibi-
tors in treating cancer, and have received widespread attention by
drug discovery companies, leading to development of small-
molecule inhibitors that speciﬁcally target epigenetic enzymes and
chromatin readers/regulators.
To allow the scientiﬁc community to have open access to newly
generated chemical probes targeting various proteins, including those
that mediate epigenetic control mechanisms, the Structural Ge-
nomics Consortium (SGC) has established a partnership with more
than ten pharmaceutical companies [10]. With a mandate to create
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well-characterised inhibitors (chemical probes) for epigenetic targets,
SGC, in collaboration with pharmaceutical companies, has devel-
oped multiple selective and potent small-molecule inhibitors
targeting epigenetic enzymes and chromatin regulators. All SGC
chemical probes are potent (<100 nM measured in biochemical or
biophysical assays), show target selectivity and display cellular ac-
tivities [10]. These properties make SGC chemical probes suitable
reagents to understand the biology of the cellular pathways that
they inhibit. Furthermore, they provide opportunities for explor-
ing the potential for such inhibitors as cancer therapeutics, either
alone or in combination with other agents.
Genotoxic drugs that either intercalate into double-strandedDNA
or induce DNA breaks by blocking enzymes at the replication fork
are widely used as chemotherapeutics for cancer treatment. For
example, topoisomerase-targetinganti-cancerdrugs suchasetoposide
anddoxorubicin are commonlyused for treating various cancer types.
Nevertheless, while these drugs are effective in killing rapidly divid-
ingcancer cellsdue to theirgenotoxicproperties, theyarealsocytotoxic
to normal dividing cells and are thus associated with bone marrow
suppression and cardiotoxicity [11]. Furthermore, etoposide has been
suggested to trap topoisomerase II β (Top2β) in addition to Top2α,
which could lead to secondary leukaemia in patients [12]. In light of
these issues, alternativeorcombinatorial approaches thatmight reduce
the dosage of these drugsmight provide new opportunities for safer
and more effective use of such chemotherapeutic agents.
Epigenetic regulators function in the context of chromatin and,
besides controlling gene expression, also play key roles in DNA rep-
lication, DNA repair and DNA-damage signalling [13]. For example,
dynamic regulation of acetylation events on histone lysines H3K56
and H4K16 has been implicated in such responses, as well as re-
cruitment of histone deacetylases HDAC1 and HDAC2 to sites of DNA
double-strand breaks (DSBs) [14]. Inhibition of these HDACs impairs
the non-homologous end joining (NHEJ) pathway of DSB repair, thus
highlighting the importance of acetylation and deacetylation events
at sites of DNA damage. More recent studies have established that
repair-pathway choice for DSBs is also strongly inﬂuenced by epi-
genetic marks [15]. For instance, SETD2 mediated trimethylation of
histone H3K36 on actively transcribing regions directs the homol-
ogous recombination (HR) machinery to repair DNA breaks in these
regions, while DSBs in intergenic or not actively transcribed regions
are repaired mainly by NHEJ [15]. These studies highlight how in-
hibiting epigenetic pathways might also deregulate certain DNA
repair pathways. Considering that both epigenetic and DNA repair
pathways are lost and/or aberrantly regulated in cancers, we
hypothesised that targeting both epigenetic and DNA repair path-
ways simultaneously might strongly impede cancer cell proliferation
and provide new opportunities for cancer therapy.
To investigate the potential of small-molecule inhibitors target-
ing epigenetic regulators for cancer treatment, we performed a
focused screen by treating human osteosarcoma cancer cells with
a library of epigenetic inhibitors obtained from SGC, in combina-
tion with the DNA damaging agents phleomycin and etoposide. This
identiﬁed the G9a inhibitor UNC0638 as hypersensitising osteosar-
coma cancer cells to phleomycin and etoposide without marked
effects on normal epithelial cells or ﬁbroblasts. Furthermore, we es-
tablished that, under low DNA damage conditions, G9a inhibition
impedes cell growth independent of p53 status, and that G9a pro-
motes NHEJ. We discuss the potential for using G9a inhibitors in
combinationwith DNA damaging agents, such as etoposide, for treat-
ing cancers either proﬁcient or defective in p53.
Materials and methods
Cell lines
Cell lines were cultured at 37 °C under 5% CO2 humidiﬁed atmosphere. U2OS,
HCT116 (p53 WT and KO), MRC5 cell lines were cultured in DMEM (Sigma-
Aldrich) containing 10% fetal bovine serum (FBS, Gibco), 100 U/ml penicillin (Gibco),
100 μg/ml streptomycin (Gibco), and 292 μg/ml L-glutamine (Gibco). RPE1 cells were
cultured in DMEM nutrient-mixture F12-HAM (Sigma-Aldrich) containing 0.23% of
sodium bicarbonate (Sigma-Aldrich) and the above-mentioned additives.
siRNA transfections
siRNA oligonucleotides were purchased fromMWG Biotech. Transfections were
performed using Lipofectamine RNAiMAX (Life Technologies) at ~40 nM ﬁnal con-
centration for 72 h. siRNA targeting Luciferase (siContl) was used as negative control.
Supplementary Table S2 provides a complete list of siRNA sequences.
IncuCyte cell proliferation assays
For screening/other sensitivity experiments, cells were seeded at ~10% conﬂu-
ence in 96-well plates and treated with compounds 24 h afterwards. After 1 h of
compound treatment, cells were treated with phleomycin (Melford Labs Ltd)/
etoposide (Sigma-Aldrich) or carboplatin (Sigma-Aldrich) and cultured in an incubator
with an IncuCyte microscopy-platform (Essen BioScience). For siRNA-transfected cell
experiments, cells were seeded onto 96-well plates 48 h post-transfection with a
similar compound/drug treatment regime. Phase-contrast images were acquired every
6 h for 6–10 days until vehicle-treated cells reached 100% conﬂuence. Cell prolif-
eration was monitored as the occupied area (% conﬂuence) of cell images over time
and calculated either as percentage conﬂuence over time or percentage growth rate
(change in % conﬂuence over a period of time).
Apoptosis assays
Cells were cultured for 3 days with different treatments and split on the third
day adding fresh compound/drug combination. After 24 h, cells were washed with
PBS and detached with PBS/2.5mM EDTA. Annexin V and propidium iodide (PI) stain-
ing was performed as per the protocol provided in the Annexin V-FITC apoptosis
detection kit (ab14085). Staining was quantiﬁed by ﬂow cytometry analysing Annexin
V-FITC binding with ﬂuorescein isothiocyanate (FITC) and propidium iodide (PI) stain-
ing by the phycoerythrin emission signal detectors.
Immunoﬂuorescence studies
U2OS cells were treated with different treatments for 3 days, reseeded on poly-
lysine coated coverslips and cultured with fresh compound/drugs for another day.
Cells were washed with PBS, ﬁxed in 4% paraformaldehyde, permeabilised with PBS/
0.2% Triton X-100 and blocked with 5% BSA/PBS containing 1% Tween-20.
Immunostaining was done with the indicated primary antibodies and appropriate
secondary antibodies both diluted in blocking buffer. Antibody details are provid-
ed in Supplementary Table S2. Images were taken with an SP5 confocal microscope
(Leica) and quantiﬁed using Volocity® 6.2.1 image analysis software (PerkinElmer).
Immunoblotting
Cell extracts were prepared with CSK buffer (10mM PIPES pH 6.8, 3 mM MgCl2,
1 mM EGTA, 0.1% Triton X-100, 300 mM sucrose and 300mM NaCl) containing 1×
protease-inhibitor cocktail (Roche), 1× phosphatase-inhibitor cocktail (Sigma-
Aldrich),10mMN-ethylmaleimide(Sigma-Aldrich)and0.25mMphenylmethylsulphonyl
ﬂuoride (PMSF, Sigma-Aldrich). Cells were washed twice with ice-cold PBS, incu-
batedwith CSKbuffer for 30min on icewith occasionalmixing, scraped and sonicated.
Equal concentrations of protein sampleswere prepared, boiled, and resolved on4–12%
Bis–Tris gradient gels (Invitrogen). Separated proteins were transferred to nitrocel-
lulose membranes (GE Healthcare) and probed with indicated antibodies.
Neutral comet assays
U2OS cells were treated with G9a inhibitor (UNC0638, 1 μM) or ATM inhibitor
(KU55933 [16], 10 μM) for 24 h, while HCT116 p53 WT/KO cells were treated for 4
days. For siRNA-transfected cells, assays were performed 72 h after transfection.
Neutral comet assay were performed with the damaging agent phleomycin, as pre-
viously reported [17]. Brieﬂy, an appropriate number of cells were mixed with low-
melting Agarose (Trevigen) and bound on GelBond ﬁlm (Lonza). Samples were lysed
and electrophoresed at 35 V for 7 min. The samples were ﬁxed, dried and stained
with SYBR Green I (Invitrogen). Images were taken with an IX71 ﬂuorescent micro-
scope (Olympus) using Cell^F software (Olympus). Tail moments were quantiﬁed
using CometScore software (TriTek). Means of tail moments of at least 50 cells were
measured per condition.
Random plasmid integration assay
Assays were performed as previously described [18]. Brieﬂy, 2 days after siRNA
transfection, U2OS cells were transfected with BamHI–XhoI-linearised pEGFP-C1
(Clontech). Cells were plated on two 15-cm plates, one for measuring seeding density
(non-selected media) and another for random integration of the plasmid (selected
with 0.5 mg/ml G418), and cultured for 10–14 days for colony formation. Transfec-
tion eﬃciency (GFP) was assessed by ﬂow cytometry. Colonies were stained with
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0.5% crystal violet/20% ethanol and counted. Random plasmid integration events were
normalised to transfection and plating eﬃciencies.
EdU click reaction for cell cycle proliferation assay
U2OS cells were pulse-labelled with 10 μM of the nucleotide analogue 5-ethynyl-
2′-deoxyuridine (EdU). EdU-incorporated cells were ﬁxed using 4% paraformaldehyde,
washed with PBS, permeabilised with 0.2% Triton X-100 for 30min, PBS washed and
treated with click-reaction mixture for 30 min in the dark. Cells were washed twice
in PBS containing 0.2% Triton-X and resuspended in PBS containing the nuclear stain
4′,6-diamidino-2-phenylindole dihydrochloride (DAPI). Detection of the newly in-
corporated nucleotide analogue was achieved via reaction of the ethynyl group with
a small ﬂuorescent azide-containing probe (Click-iT® EdU Alexa Fluor® 647 Imaging
Kit no. C10340; Invitrogen). Percentages of cells in different cell cycle stages were
measured by ﬂow cytometry using a BD LSRFortessa cell analyser (BD Biosciences).
Homologous recombination assay
Homologous recombination (HR) eﬃciency under control conditions, or upon
G9a inhibition or depletion was monitored using the Traﬃc Light Reporter (TLR)
system [19]. The assay was performed as described previously [20]. The TLR report-
er system, stably integrated in U2OS cells, comprises a mutant GFP (green-
ﬂuorescent protein) gene with a unique recognition site for the endonuclease I-SceI.
Upon transient expression of I-SceI, the repair of the induced DSB can generate a
functional GFP gene when HR occurs through use of sequences in a co-transfected
donor plasmid, which contains a truncated GFP functional for the part mutated in
the reporter system. Therefore, GFP expression was used as a read-out for HR eﬃ-
ciency. U2OS TLR cells were treated with the indicated siRNA or inhibitor, and 6 h
later were co-transfected with infrared ﬂuorescent protein (IFP)-I-SceI endonucle-
ase and blue ﬂuorescent protein (BFP)-donor plasmid. Cells were harvested 72 h after
siRNA transfection. Percentages of GFP+ (HR) cells were measured by ﬂow cytometry
using a BD LSRFortessa cell analyser (BD Biosciences). Approximately 10,000 doubly
transfected (IFP+ and BFP+) cells were scored for each condition in three indepen-
dent experiments. Results were normalised to Control siRNA or vehicle treated cells.
Statistical and quantitative analysis
Statistical analyses were done by unpaired Student’s t-test. For quantitative anal-
ysis, all values representmeans of three independent experiments ±standard deviation
(SD).
Results
To assess the impact of recently developed epigenetic probe com-
pounds on DNA repair and related processes, we obtained a library
of eleven small-molecule compounds from the SGC that inhibit the
activity of a series of distinct epigenetic regulators. These com-
pounds, which impact on histone acetylations, methylations or
chromatin–protein interactions, were generated to possess a target
speciﬁcity of more than 30-fold over other proteins in the same
protein family and activity in cells below 1 μM. Details of the target
speciﬁcity and cellular activity of the probes used in this study are
available on the SGC website (http://www.thesgc.org/chemical
-probes/epigenetics).
To explore the effects of these compounds on cellular responses to
DNA damage, we assessed their impacts on the sensitivity of human
osteosarcomaU2OScancercells toagents thatgenerateDNADSBs. First,
weassayed for thecytotoxicityof probecompounds towardsU2OScells
by treating themwith various doses of the epigenetic probes. Thus,we
used 50 μM as the highest concentration and serially diluted each in-
hibitor three-fold to reach 20 nM, thereby generating dose-dependent
survival curves to determine each compound’s IC50 value (the con-
centrationthat ledtoa50%dropincell survival).Thedetailsof theprobes
used, their speciﬁc targets, references and IC50 values calculated for
U2OS cells are provided in Supplementary Table S1. Based on the cal-
culated IC50 values and data provided by SGC for each of the probes in
other cell lines (availableon theSGCwebsite),weused1μMas thecon-
centration for each compound for subsequent drug-combination
screening. For combination studies, we chose concentrations of DNA-
damagingagentphleomycin thatwerenotoverly toxic to theU2OScells
butdidproducecytotoxicitywhencombinedwith inhibitorsof theDDR
kinasesATMorATR (data not shown).We thus chose 0.5 μMand1 μM
of phleomycin as concentrations for the drug-combination screen.
Next, we carried out combination drug screening by plating U2OS
cells to ~10% conﬂuence, then 24 hours later adding probe com-
pounds for 1 hour before adding phleomycin (Fig. 1A). Cells were
then assessed for growth by phase-contrast imaging every 6 hours
for several days. Fig. 1B depicts ensuing data for epigenetic probe
inhibitors targeting chromatinmodulators (PFI-1, GSK2801, UNC1215,
PFI-3), histone acetyl-transferases (I-CBP112, SGC-CBP30) and histone
methyl-transferases (UNC0638, SGC0946, GSK343, PFI-2, UNC1999).
Strikingly, while most probes had little or no effect on cell growth
in these studies, UNC0638 markedly hypersensitised U2OS cells to
phleomycin in a dose-dependent manner (Fig. 1B). UNC0638 is a
substrate-competitive inhibitor that inhibits the catalytic activity
of the G9a/GLP histone methyl-transferase, which has been found
to mainly generate dimethylation of lysine residue 9 of histone H3
(H3K9me2) [21]. The structure of UNC0638 and a co-crystal struc-
ture of the inhibitor bound to the G9a catalytic domain are provided
in Supplementary Fig. S1.While it remains to be determinedwhether
the other probe compounds we tested have effects in combination
with other DNA-damaging drugs, we selected UNC0638 for our
further analyses, as described below.
Fig. 1. Screening chemical probe inhibitors identiﬁes UNC0638 as potentiating with phleomycin to impede cell proliferation. (A) Schematic elaborating the screening strat-
egy. (B) U2OS cells were seeded in 96 well plates at ~10% conﬂuence and treated with vehicle (1% DMSO), small-molecule inhibitors targeting chromatin modulators (Chr.
Regulators; PFI-1, GSK2801, UNC1215, PFI-3), histone acetyl-transferases (HATs; I-CBP112, SGC-CBP30) and histone methyl-transferases (UNC0638, SGC0946, GSK343, PFI-
2, UNC1999). Details of inhibitors used are provided in Supplementary Table S1. One-hour post treatment, cells were damaged with low doses of phleomycin (0.5 μM or
1 μM) and were allowed to proliferate for 6 days. The area occupied by cells (% conﬂuence) over time is a surrogate marker for proliferation. Data presented here provide
percentage growth rates of cells over a period of 6 days. Error bars correspond to SDs of three independent experiments. Small-molecule Inhibitor UNC0638 inhibiting G9a
methyl-transferase hypersensitised U2OS cells to DSB-inducing agent phleomycin at both phleomycin concentrations tested.
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As indicatedbygrowth curves (Fig. 2A),UNC0638 treatmentmark-
edly inhibited the growth of U2OS cells in the presence of low levels
of phleomycin but had little or no effect on cell growth in the absence
of phleomycin.At theend-pointof this experiment, plateswere stained
with DAPI to monitor the total number of cells after different treat-
ments, thereby demonstrating that cell growth inhibition was also
associatedwith inhibitionof proliferation as evidencedby therebeing
considerably reduced numbers of cell nuclei (Fig. 2B). The function-
ality of G9a inhibitor UNC0638 in this study was established by us
observing that it reduced cellular levels of dimethylation of histone
H3K9 as measured by western immunoblotting (Fig. 2C).
Next, we investigated whether the effect for UNC0638 in combi-
nation with phleomycin also extended to combinations with other
clinicalDNA-damaging agents. Thus,weperformedcell growthassays
in a similar manner but with etoposide, a Topoisomerase II inhibitor
that generates enzyme-boundDSBs, orwith carboplatin that induces
inter- and intra-strandDNAcrosslinks.Notably, UNC0638affected cell
growth when combined with etoposide (Fig. 2D) but not with
carboplatin (Fig. 2E) suggesting that G9a plays a speciﬁc role in DNA
DSB repair. While UNC0638 enhanced the induction of markers of
DNA damage caused by treating cells with phleomycin, it had little
or no effect on suchmarkerswhen combinedwith carboplatin (Sup-
plementary Fig. S2A and B). Interestingly, this growth inhibitory
potentiating effect of UNC0638 with DSB-inducing agents showed
speciﬁcity for U2OS cancer cells, as this effect was absent or not as
strong in non-tumorigenic RPE-1 (retinal pigment epithelial) cells or
MRC5cellsderived fromlungﬁbroblasts (SupplementaryFig. S3). These
observations thus highlighted the potential for G9a inhibition by
UNC0638 and derivatives to speciﬁcally inhibit tumour cell growth
in combination with low levels of DSB-inducing agents.
To gain some assurance that the responses we observed were
not due to an off-target effect of UNC0638, we used another small-
molecule G9a inhibitor of a different structural chemotype, A-366
[22]. Importantly, A-366 produced similar potentiating effects on
U2OS cell growth and damage accumulation, when combined with
phleomycin as we observed with UNC0638 (Fig. 2F, Supplementa-
ry Fig. S2C). However, while UNC0638 had effects at 1 μM, A-366
only displayed activity when used at the higher concentration of
10 μM. Because of its greater potency in these assays in combina-
tion with phleomycin, we focused on the G9a inhibitor UNC0638
in our ensuing studies. To further validate our conclusion that the
potentiating effects of UNC0638 and A-366 were being mediated
by them targeting G9a, we depleted G9a in U2OS cells by using three
independent short-interfering RNAs (siRNAs) and evaluated the sen-
sitivities of control and depleted cells to phleomycin or etoposide.
Western immunoblot analyses established that the three siRNAs pro-
duced comparable eﬃciencies of G9a depletion and concurrent
reduction in levels of H3K9me2 (Fig. 2G). Importantly, while low
levels of phleomycin or etoposide did not appreciably affect the
growth of U2OS cells transfected with control siRNA (siContl), each
of the three siRNAs targeting G9a (siG9a -1, 2, 3) resulted in sig-
niﬁcant sensitisation to both phleomycin and etoposide (Fig. 2H).
Furthermore, unlike the situation in control cells, where UNC0638
caused sensitisation to phleomycin, UNC0638 had little impact in
further sensitising cells that had been pre-treated with siRNAs to
deplete G9a. This “epistatic” relationship between G9a depletion and
UNC0638 treatment thus further established the on-target effect of
small-molecule mediated G9a inhibition (Fig. 2I).
Next, we explored how the combinatorial treatment of UNC0638
and DSB-inducing agents impeded tumour cell growth, considering
mechanisms impacting on cell-cycle arrest, senescence, apoptosis or
othermodesof cell death.Weﬁrst assessedwhetherU2OS cellsmight
undergo apoptosis when co-treated with phleomycin and UNC0638
(cells treated with vehicle, 1% DMSO, served as a control). UNC0638
is a reversible inhibitor and is stable for at least 3 days in cell culture
conditions [21]. Thus, after treating U2OS cells with phleomycin and
UNC0638 alone and in combination for four days, cells were doubly
stained for FITC-conjugatedAnnexinVandpropidium iodide (PI), then
were analysed by ﬂow cytometry to monitor apoptotic cells.
Externalisation of Annexin V is a readout of early stages of apopto-
sis, while cells that lose cell membrane integrity show positive PI
staining. We observed a signiﬁcant increase in the percentage of
Annexin V/PI doubly positive cells upon co-treatment of UNC0638
in the presence of low concentrations of phleomycin compared to
cells treated with phleomycin or UNC0638 alone (Fig. 3A and Sup-
plementaryFig. S4).However,wedidnotobservea signiﬁcant increase
in the percentage of Annexin V singly-positive cells upon co-
treatment of UNC0638 and phleomycin (data not shown), which
suggested that the mode of cell death was independent of early
apoptotic processes that are mainly mediated by p53.
To directly test the relevance of p53 in mediating the observed
cell death, we used HCT116 colorectal carcinoma cells inactivated
for the TP53 gene (p53 KO) [23] as well as HCT116 cells with wild-
type p53 (p53WT). Notably, we observed that combined treatment
of UNC0638 and phleomycin impeded cell growth independent of
p53 status (Fig. 3B). Furthermore, we observed similar increases in
Annexin V/PI doubly-positive cells upon co-treatment with UNC0638
and phleomycin in both wild-type and TP53 knockout cells (Fig. 3C
and Supplementary Fig. S4). This suggested that the cell death
induced by the combinatorial treatment was via a p53 indepen-
dent mechanism, which could be necrosis or p53 independent
apoptosis. This conclusion was further strengthened by our obser-
vation that combined treatment with UNC0638 and phleomycin led
to no detectable increase in cleavage of poly(ADP-ribose) poly-
merase 1 (PARP1), which is a well established target of p53mediated
caspase-3 activity [24] compared to phleomycin treatment only
(Fig. 3D).We also assessedwhether combined treatment of UNC0638
with phleomycin might affect the cell cycle status of cancer cells.
Indeed, combined treatment of phleomycin with G9a inhibitor
induced G2 accumulation as determined by FACS analysis of cells
incorporating the nucleotide analogue EdU co-stained with DAPI
(Supplementary Fig. S5). Thus, these ﬁndings revealed that G9a in-
hibition in the presence of low levels of phleomycin induces both
damage induced G2 delay and p53 independent cell death.
To explore the possibility that UNC0638 was inhibiting the
repair of DSBs produced by phleomycin, we took advantage of
Fig. 2. G9a inhibition potentiates the anti-tumour activity of DSB-inducing agents. (A) Growth curves for U2OS cells show that co-treatment of UNC0638 (1 μM) with phleomycin
(1 μM) signiﬁcantly inhibits tumour cell growth compared to cells treated with phleomycin alone. (B) Representative images of DAPI stained cell nuclei at the end-point of
the proliferation assay are shown. (C) Western blot analysis reveals a reduction in levels of histone H3K9 dimethylation (H3K9me2) upon UNC0638 treatment. Total levels
of histone H3 and tubulin served as loading controls. (D and E) Growth curves of U2OS cells demonstrate that co-treatment of UNC0638 (1 μM) hypersensitised tumour
cells to etoposide (100 nM) but not carboplatin (15 μM). At the same concentrations of phleomycin and etoposide, UNC0638 did not adversely affect the cell growth of non-
tumorigenic RPE1 and MRC5 cells (see Supplementary Fig. S3). (F) Structurally distinct chemotype of G9a small-molecule inhibitor, A-366, similarly hypersensitises U2OS
cells to phleomycin. (G) Western blots conﬁrm G9a depletion and corresponding reductions in H3K9 dimethylation (H3K9me2) upon treatment of U2OS cells with three
independent siRNAs (siG9a-1, 2, 3) compared to control siRNA-transfected cells (siContl). Tubulin and total histone H3 were used as loading controls. (H) Depletion of G9a,
the target of UNC0638 and A-366, with three independent siRNAs (siG9a-1, 2, 3) hypersensitises U2OS cells to phleomycin (1 μM) and etoposide (100 nM) compared to
control siRNA-transfected cells (siContl). Histograms depict % conﬂuence of cells at the endpoint of the proliferation assays. (I) Histograms provide the % conﬂuence of cells
at the endpoint of the proliferation assays with indicated treatments of U2OS cells showing that UNC0638 does not further increase the hypersensitivity of G9a depleted
cells (siG9a-1, 2, 3) to phleomycin (1 μM) supporting the effects of UNC0638 being via G9a inhibition. Error bars correspond to standard deviations (SDs) of three indepen-
dent experiments. Non-signiﬁcant p-values are represented as ns.
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the fact that unrepaired DSBs lead to the presence of subnuclear
DNA-repair foci that can be visualised by staining for proteins
such as 53BP1 or the DNA-damage generated, serine 139-
phosphorylated derivative of histone H2A termed γH2AX [25].
Thus, we treated U2OS cells with UNC0638 and phleomycin alone
or in combination for four days, and then we carried out indirect
immunoﬂuorescence staining for the DSB-markers 53BP1 and γH2AX.
This revealed that cells co-treated with phleomycin and UNC0638
exhibited signiﬁcantly increased numbers of γH2AX and 53BP1
foci compared to cells treated with phleomycin only (Fig. 4A and
B), suggesting that they experienced higher levels of unrepaired
DSBs.
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Fig. 3. Under low damage condition UNC0638 induces tumour cell death independent of p53 status. (A) U2OS cells were treated as indicated for 4 days and stained with
Annexin V and PI for ﬂow cytometry analyses. Combined treatment of UNC0638 (1 μM) and low dose phleomycin (1 μM) signiﬁcantly increases U2OS cell death as mea-
sured by percentage of Annexin V/propidium iodide double-positive cells compared to cells treated with phleomycin alone. Error bars correspond to SDs of three independent
experiments. (B) Growth curves for HCT116 p53+/+ (WT) and p53−/− (KO) cells with indicated treatments show that co-treatment of UNC0638 (1 μM) with phleomycin
(0.5 μM) inhibits growth of HCT116 cells independent of p53 status. Representative phase-contrast images of cells at the end-point of the conﬂuence assay are shown. (C)
HCT116 p53 WT and KO cells were treated with indicated treatments for 4 days and stained with Annexin V and PI for ﬂow cytometry analyses. UNC0638 treatment in the
presence of low dose phleomycin increases the cell death (% Annexin V/propidium iodide double-positive cells) for both p53 WT and KO cells compared to phleomycin
treatment alone. Statistical analyses were performed as in (A). (D) No increase in PARP1 cleavage was observed upon co-treatment of UNC0638/phleomycin compared to
phleomycin treatment only. See also Fig. S4.
Fig. 4. G9a inhibition impairs DNA DSB repair via NHEJ. (A) Representative immuno-ﬂuorescent images of U2OS cells stained with antibodies recognising 53BP1, γH2AX
and nuclear stain DAPI (all in grey) after indicated treatments for 4 days are shown. Dotted lines mark nuclear peripheries and the scale bar represents 10 μm. (B) Quan-
tiﬁcation of average numbers of γH2AX and 53BP1 foci per cell upon the treatments indicated in (A). Error bars correspond to SDs of three independent experiments (>100
cells were analysed per condition per experiment). Combined treatment of UNC0638 with phleomycin signiﬁcantly increases the average number of γH2AX and 53BP1 foci
per cell compared to phleomycin treatment alone. (C and D) DNA repair eﬃciencies were assayed by neutral comet assay. After the indicated treatments, U2OS and HCT116
p53 WT and KO cells were damaged with phleomycin (26 μM) for two hours (damaged), and were allowed to repair for 2 hours (recovery) after washing off the phleomycin,
in the presence of indicated treatments. DSB repair eﬃciency was measured as the ratio of comet tail moments in recovery by damaged condition. UNC0638 treatment
impaired DSB repair both in U2OS and HCT116 cells. (E) Depletion of G9a using three independent siRNAs (siG9a-1, 2, 3) impaired DSB repair upon phleomycin treatment.
Depletion of ATM Kinase (siATM) served as a positive control. Comet assays were conducted as in (C). (F) Percentage eﬃciency of NHEJ upon depletion of G9a with three
independent siRNA (siG9a-1, 2, 3) measured by random plasmid integration. Depletion of XRCC4 (siXRCC4) and control siRNA (siContl) served as positive and negative con-
trols, respectively. Error bars correspond to SDs of three independent experiments. See also Fig. S6.
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Although other explanations were possible, the above data sug-
gested that, over several rounds of DNA replication in the presence
of low levels of phleomycin, DSBs were produced in U2OS cells and
were resolved by a mechanism(s) that was impaired by G9a inhi-
bition. To explore this model, we testedwhether UNC0638 treatment
affected DSB repair by using neutral comet assays. Thus, after cells
weremock-treated or treatedwith phleomycin for 2 hours (damaged
condition), phleomycin was removed by washing and cells were
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incubated for a further two hours to allow DSB repair to proceed
(recovery). Comet-tail moments were then analysed in the various
samples, and the ratio of comet-tail moments at recovery to damaged
time-point provided a measure of DNA repair eﬃciency (ATM in-
hibitor KU55933 [16] was used as a positive control to conﬁrm the
functionality of the assay). Ensuing analyses demonstrated that treat-
ment with G9a inhibitor UNC0638 impaired the eﬃciency of DSB
repair in U2OS cells (Fig. 4C) as well as in HCT116 cells with or
without functional p53 (Fig. 4D). Furthermore, depleting G9a using
any of three independent siRNAs also led to DSB repair defects as
measured by neutral comet assays (Fig. 4E; representative images
showing tail moments of single cells quantiﬁed for Fig. 4C–E are de-
picted in Supplementary Fig. S6A–C). By western blot analyses, we
also observed retention of DNA damage induced phosphoryla-
tions of ATM, KAP1 and CHK2 (p-ATM, p-KAP1 and p-CHK2) as well
as γH2AX in cells treated with G9a inhibitor or G9a siRNAs com-
pared to vehicle or control siRNA treated cells (Supplementary
Fig. S6D).
In light of these data and because most DSBs in human cells are
repaired by the pathway of non-homologous end joining (NHEJ),
we assessed the eﬃciency of this pathway by a random plasmid in-
tegration assay [26]. This assay speciﬁcally determines NHEJ because
it involves genomic integration of a linearised GFP-bearing plasmid
with no extensive homology to the human genome. By using this
assay, we found that NHEJ was substantially reduced by siRNA-
mediated depletion of G9a (Fig. 4F). While NHEJ repairs DSBs in all
cell cycle phases, damage in S/G2 cells is repaired by homologous
recombination (HR). We tested if G9a depletion might affect the HR
eﬃciency by quantifying integration of an HR donor plasmid by using
the Traﬃc Light Reporter (TLR) system [19,20] (Supplementary
Fig. S7A and B). While we observed a mild HR defect upon G9a de-
pletion, inhibiting G9a catalytic activity with UNC0638 did not
signiﬁcantly affect HR eﬃciency (Supplementary Fig. S7C; note that
these assays were controlled for effects on the proportion of cells
in S/G2). Collectively, these results pointed to a role of G9a in pro-
moting DSB repair mainly by NHEJ.
Discussion
In this study, we have established that G9a inhibition together
with induction of low-level DNA damage by the DSB-inducing agents
phleomycin or etoposide selectively impedes tumour cell growth
without markedly affecting the growth of the normal epithelial cells
or ﬁbroblasts that we tested. Our study supports a model in which
inhibition of G9a catalytic activity prevents repair of DSBs and pos-
sibly other forms of DNA damage, leading to damage persistence
and ensuing reduced proliferation and death of cancer cells. We also
show that this enhanced growth inhibition of cancer cells by DSB-
inducing agents in the presence of UNC0638 is independent of p53
status. A previous study reported that depleting G9a using short-
hairpin RNA approaches in colorectal cell lines HT29 and SW620
induced endogenous DNA damage [27]. However, in our study, we
did not observe pronounced induction of DNA damage either by
siRNA-mediated depletion of G9a or by using the catalytic inhibi-
tor UNC0638 in two different cell lines: osteosarcoma U2OS and
colorectal HCT116 cells.We speculate that the differences in our ﬁnd-
ings and those in the published report could be due to differences
in experimental conditions or cancer cell lines used.
To develop a deeper understanding of the therapeutic poten-
tial for G9a inhibition, knowledge of tumour cell selectivity will be
critical. While we observed no signiﬁcant effect on growth poten-
tial of normal ﬁbroblasts and epithelial cells upon combined
treatment with G9a inhibitor/DSB agents at the doses we used, it
will be important to test this and other combinations on larger col-
lections of non-transformed and transformed cells. Nevertheless,
by using isogenic p53 cell models, we found that the potentiating
effects of G9a inhibition in the context of phleomycin were inde-
pendent of p53 status, with tumour cells either proﬁcient or deﬁcient
in p53 being similarly hypersensitised to phleomycin by G9a inhi-
bition. Mutation or deﬁciency in p53 is associated with resistance
to chemotherapy [28], and hence targets that might impede tumour
cell growth independent of p53 may have considerable potential
in the clinic.
We found that inhibiting G9a per se did not lead to detectable
accumulation of DNA DSBs in cells as reﬂected by γH2AX and
53BP1 focus formation or by comet assays. Instead, our data indi-
cate that it is only in the presence of a DNA-damaging agent such
as phleomycin that G9a inhibition markedly affects cell prolifera-
tion, by inhibiting DSB repair. We found that the NHEJ pathway
of DSB repair is markedly affected by G9a depletion, although it
remains to be determined precisely how and at which step(s) G9a
operates to enhance this repair pathway. As a major role for G9a
is to mediate methylation of H3K9, we investigated whether im-
pairment of DSB repair might reﬂect a reduction in this chromatin
mark, global chromatin decompaction and concurrent transcrip-
tional activation. However, we observed no marked reduction of
H3K9 methylation within 24 hours of G9a inhibitor treatment,
while this treatment was suﬃcient to impair DSB repair in U2OS
cells. In addition, G9a inhibition/loss did not alter the protein
levels of DDR proteins, such as DNA-PKcs, Ku80, XRCC4 and XLF,
which are crucial for repairing DSBs by NHEJ (Supplementary Fig. S8).
These ﬁndings suggest that themechanism bywhich G9a inhibition/
loss impairs DSB repair might be independent of global changes
in chromatin compaction and associated alterations in gene ex-
pression. In this regard, we note that G9a also methylates non-
histone proteins [29], some of which are already identiﬁed. It is
therefore possible that G9a driven methylation of a non-histone
proteins – and perhaps intrinsic components of the NHEJ appara-
tus – could cause this repair defect, a scenario that we are currently
investigating.
In conclusion, our ﬁndings highlight the potential for using small-
molecule inhibitors of G9a in combination with certain DNA-
damaging chemotherapeutic agents. More broadly, our data promote
the idea of testing epigenetic compounds not just as individual agents
but also in combination with other chemotherapeutics. As epigen-
etic events participate in all processes occurring on chromatin, it
will be interesting to extend studies to test synergies of epigen-
etic probes with agents that generate other forms of DNA damage
and/or which impede DNA replication. Furthermore, there is the po-
tential to also explore the combinatorial potential of epigenetic probe
compounds with other chemotherapeutic drugs targeting a diver-
sity of other cancer-relevant processes. In addition to providing
insights into aspects of cell biology, such studies may provide ad-
ditional ways to study cancer related processes, identify medical
implications of combinatorial treatment regimens and provide op-
portunities for developing new cancer therapies.
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